Gsk Plc ADR
About GlaxoSmithKline plc
Glaxo has 3 core businesses - Pharmaceuticals, Vaccines and Consumer Healthcare. The company has made significant progress in expanding its presence in emerging markets by acquiring product portfolios from companies like Bristol-Myers and UCB. In August 2019, Glaxo and Pfizer merged their consumer healthcare unit into a new JV. Glaxo owns a controlling stake in the JV. Glaxo plans to split itself into two standalone companies. The new Glaxo will be a biopharma company. Glaxo intends to separate its Consumer Healthcare segment into a standalone company in 2022. The independent Consumer Healthcare company will be named Haleon. In 2015, Glaxo divested two quadrivalent meningitis ACWY vaccines ' Nimenrix and Mencevax ' to Pfizer, a portfolio of OTC brands to Perrigo, and all its remaining rights to Arzerra for auto-immune indications including multiple sclerosis to Novartis. In January 2019, Glaxo acquired Tesaro, an oncology focused biotech company, which added the PARP inhibitor Zejula to its portfolio.
